EyeGene Inc (185490) - Total Assets
Based on the latest financial reports, EyeGene Inc (185490) holds total assets worth ₩56.60 Billion KRW (≈ $38.36 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 185490 net asset value for net asset value and shareholders' equity analysis.
EyeGene Inc - Total Assets Trend (2014–2024)
This chart illustrates how EyeGene Inc's total assets have evolved over time, based on quarterly financial data.
EyeGene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
EyeGene Inc's total assets of ₩56.60 Billion consist of 54.1% current assets and 46.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩561.42 Million | 1.3% |
| Accounts Receivable | ₩1.64 Billion | 2.5% |
| Inventory | ₩584.99 Million | 0.9% |
| Property, Plant & Equipment | ₩9.31 Billion | 14.3% |
| Intangible Assets | ₩4.28 Billion | 6.6% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how EyeGene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EyeGene Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EyeGene Inc's current assets represent 54.1% of total assets in 2024, a decrease from 84.8% in 2014.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2024, down from 46.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 14.3% of total assets.
EyeGene Inc Competitors by Total Assets
Key competitors of EyeGene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
EyeGene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.19 | 5.55 | 4.25 |
| Quick Ratio | 3.13 | 5.46 | 4.17 |
| Cash Ratio | 0.00 | 0.08 | 0.00 |
| Working Capital | ₩19.21 Billion | ₩30.30 Billion | ₩27.63 Billion |
EyeGene Inc - Advanced Valuation Insights
This section examines the relationship between EyeGene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -16.4% |
| Total Assets | ₩65.31 Billion |
| Market Capitalization | $29.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values EyeGene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: EyeGene Inc's assets decreased by 16.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for EyeGene Inc (2014–2024)
The table below shows the annual total assets of EyeGene Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩65.31 Billion ≈ $44.26 Million |
-16.38% |
| 2023-12-31 | ₩78.10 Billion ≈ $52.93 Million |
-2.83% |
| 2022-12-31 | ₩80.38 Billion ≈ $54.47 Million |
-23.44% |
| 2021-12-31 | ₩104.99 Billion ≈ $71.15 Million |
+136.32% |
| 2020-12-31 | ₩44.43 Billion ≈ $30.11 Million |
-6.09% |
| 2019-12-31 | ₩47.31 Billion ≈ $32.06 Million |
-12.46% |
| 2018-12-31 | ₩54.04 Billion ≈ $36.62 Million |
+78.46% |
| 2017-12-31 | ₩30.28 Billion ≈ $20.52 Million |
+63.20% |
| 2016-12-31 | ₩18.56 Billion ≈ $12.58 Million |
-23.72% |
| 2015-12-31 | ₩24.33 Billion ≈ $16.49 Million |
+338.90% |
| 2014-12-31 | ₩5.54 Billion ≈ $3.76 Million |
-- |
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more